[EN] CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS [FR] CYCLOALKYLNITRILE PYRAZOLOPYRIDONES UTILISÉES COMME INHIBITEURS DE LA JANUS KINASE
合成并表征了稀土金属(Y,La,Sm和Lu)与手性三齿酰胺基芴基配体的配合物。在非常温和的条件下,这些络合物在催化非活化烯烃的分子内加氢胺化和酮的氰基甲硅烷基化方面均显示出高效率,但是,没有实现对映体控制。反应过程的1 H NMR监测表明,芴基部分的弱配位能力可能是造成这种转化中手性配合物缺乏不对称诱导能力的原因。
A structurally characterized cationic aluminium complex [(AT)Al(DMAP)]+[OTf]- (3) stabilized through less bulky aminotroponate (AT) ligand is reported (DMAP = 4-(dimethylamino)pyridine). It works as an excellent mononuclear main-group catalyst (1 to 2 mol%) for the cyanosilylation of a variety of aldehydes and ketones by consuming just 5 to 30 min at room temperature.
BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
申请人:Hilpert Kurt
公开号:US20140073651A1
公开(公告)日:2014-03-13
The invention relates to benzamide derivatives of formula (I),
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.
Mild and Efficient Trimethylsilylcyanation of Ketones Catalysed by PNP Chloride
作者:Marie-Agnès Lacour、Nicolas J. Rahier、Marc Taillefer
DOI:10.1002/chem.201101195
日期:2011.10.24
Mild & green: The commercially and readily available PNPCl behaves as a very effective catalyst for the synthesis of various trimethylsilyl cyanohydrins from a wide range of aliphatic, cyclic, α,β‐unsaturated and aromatic ketones. The method proceeds at room temperature in solvent‐free conditions, in the presence of very small amounts of catalyst (see scheme).
The ability of a platinum compound to act as a catalyst for the cyanosilylation of carbonyl compounds is demonstrated through a well-defined germylene stabilized Pt(II) dicyanide, trans-(iBu)2ATIGe(iPr)}2Pt(CN)2.
[EN] BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE BENZAMIDE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2012114268A1
公开(公告)日:2012-08-30
The invention relates to benzamide derivatives of formula (I),wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.